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Ulcerative colitis (UC) is characterized by a long-standing chronic course with remissions and exacerbations. Previously,
patients do not respond to 5-aminosalicylic acid compounds and corticosteroids are considered for colectomies, however, in
recent years, alternative treatments emerged for steroid-refractory or steroid-dependent UC. In this review article, we focus on
immunomodulators (such as azathioprine [AZA] and 6-mercaptopurine [6-MP]) and immunosuppressants (such as cyclosporine
A [CSA] and tacrolimus [FK506]) for steroid-refractory or steroid-dependent ulcerative colitis. The characteristics, eﬃcacy and
adverse eﬀects of these drugs are outlined. Although the randomized trial of FK506 is conducted in Japan, the clinical data of
CSA in Japanese patients are limited. The short-, mid- and long-term follow-ups of CSA administration in Japanese patients
are discussed. As for thipurine drugs, the clinical importance of multidrug-resistance protein 4 (MRP4) in Japanese patients is
highlighted.
1.Introduction
Ulcerative colitis (UC) is characterized by a long-standing
chronic course with remissions and exacerbations. Approx-
imately 15% of patients have severe attacks requiring
hospitalization at some time during their disease course.
These patients are traditionally treated with intravenous
corticosteroids, with a response rate of approximately 60%.
Previously, patients do not respond to 5-aminosalicylic
acid compounds and corticosteroids are considered for
colectomies, however, in recent years, alternative treatments
emerged for steroid-refractory or steroid-dependent UC;
immunomodulators (such as azathioprine [AZA] and 6-
mercaptopurine [6-MP]), immunosuppressants (such as
cyclosporine A [CSA] and tacrolimus [FK506]), and anti-
TNFα-antibody (inﬂiximab).
In this part, we focus on immunomodulators and
immunosuppressants. Unfortunately we have never used
methotrexate before and have little experience on anti-
TNFα-antibody. Therefore these two agents are excluded.
Immunomodulators and immunosuppressants are essential
for the induction and maintenance of UC. For induction
therapy, CSA and FK506 are mainly used because of their
rapid onset of eﬀectiveness. On the other hand, AZA and 6-
MP (sometimes FK506) are used in the maintenance therapy
of UC. AZA and 6-MP have a slow onset of action and
are therefore usually ineﬀective in acute disease ﬂare-ups. In
this paper, the characteristics and usage of these drugs are
described focusing on Japanese patients.
2.CalcineurinInhibitors(CNI)
2.1. Cyclosporin A (CSA). CSA blocks the calcium-depend-
ent signal-transduction pathway emanating from the T-cell
receptor, thereby inhibiting the action of helper T cells.
CSA is administrated for the patients with graft-versus-
host disease after allogeneic bone marrow transplantation
or the patients with renal transplant. As for ulcerative
colitis, the induction of CSA for severe, steroid-refractory2 ISRN Gastroenterology
UC has provided an eﬀective medical alternative to patients
previously faced with only surgical options. Uncontrolled
trials [1, 2] and controlled trials [3] established the eﬃcacy
of short-term CSA use as “rescue therapy” in severe UC.
Lichtiger et al. reported intravenous CSA followed by oral
therapy showed an initial response rate of 82% within
a mean of 7 days versus 0% in a group that received
steroidsalone.QualityoflifeanalysescomparingUCpatients
treated with CSA to those who underwent colectomies have
shown that CSA patients consistently score as well as, or
better than, their surgical counterparts [4]. We have started
CSA administration for refractory UC patients since 1999
according to Lichtiger’s method [3].
Prior to CSA administration, cytomegalovirus infec-
tion should be checked by using cytomegalovirus anti-
genemia (C7-HRP), PCR, or immunohistochemistry for
cytomegalovirus from endoscopic biopsy specimens. If
cytomegalovirus infection is suspected, dose reduction of
prednisolone (PSL) and administration of ganciclovir are
recommended. In our hospital, CSA was administrated by
continuous infusions with starting doses of 2mg/kg per
day for a maximum of 14 days. Serum CSA levels were
monitored three times a week during infusion therapy and
the infusion dose was altered by aiming for 350–450ng/mL.
AftersuccessfulcontinuousCSAinfusions,weswitchedfrom
continuous infusions to oral dosing. Total oral daily doses
were double those of continuous daily infusions. Trough
serum levels were monitored and the dose of CSA was
adjusted to trough serum levels of 100–200ng/mL.
We have reviewed medical charts and the recent followup
of 41 patients who had been administrated CSA for disease
ﬂare-ups between 1999 and 2009. The response rate at 2
weeks after CSA administration was 71%. CSA responders
were deﬁned as those with a 50-point decrease during
continuous CSA infusions in Seo’s complex integrated
disease activity index (CIDAI) [5]. A background analysis
was performed on 37 patients without early CSA discontin-
uation and revealed three prognostic factors: (i) more than
10,000mg of PSL used before starting CSA; (ii) positivity for
C7-HRP; (iii) disease duration of more than 4 years [6]. The
relapsewithin1yearafterCSAadministrationissigniﬁcantly
suppressed by the addition of azathioprine (AZA) (72.5%
versus 26.7, P = .0237, log-rank test). The addition of AZA
after CSA treatment signiﬁcantly reduced the colectomy rate
(66.7% versus 30.5%, P = .0419, log-rank test). Among
CSA responders, AZA na¨ ıve patients had signiﬁcant lower
probabilities for colectomies compared to patients with prior
AZA treatment (22.5% versus 56.7%, P = .0309, log-rank
test) [6]. Our result revealed factors aﬀecting the eﬃcacy
of CSA therapy for patients with refractory UC. AZA is
important agent that maintains disease quiescence once one
responds to CSA. However, refractory patients, despite AZA
treatment, are more likely to have consequent colectomies.
In our hospital, low dose of sulfamethoxazole-trimetho-
prim complex (400mg of sulfamethoxazole and 80mg of
trimethoprim per day) is administrated prophylactically
to the patients who is under treatment with calcineurin
inhibitors. Therefore we have no experience of severe
infectious diseases such as Pneumocystis carinii infection.
Among 41 patients, discontinuation of CSA was experienced
in one case with renal dysfunction and two cases with liver
dysfunction.
2.2. Tacrolimus (FK506). FK506 has similar pharmacological
mechanisms to CSA. Fellermann et al. reported the eﬀec-
tiveness of intravenous or oral FK506 for steroid refractory
UC patients with doses of 0.01-0.02mg/kg per day or 0.1-
0.2mg/kg/day, respectively [8]. Ogata et al. have reported
the results of a placebo-controlled double blind study which
revealed that oral FK506 improved in disease activity for
68.4% in the high trough group compared with 10.0% in
the placebo group (P<. 001) [9]. In the high trough group,
20.0% of patients had clinical remission and 78.9% had
mucosal healing. In the open label extension, 55.2% of all
patients had an improved disease activity score at week 10.
FK506 also had steroid sparing eﬀect. The most common
adverse event was mild ﬁnger tremor.
In Japan, oral FK506 became an alternative for refractory
UC from July in 2009 under national health insurance. Oral
FK506 has slower onset of action compared to intravenous
CSA. This is because serum level of FK506 reached high
trough (10–15ng/mL) after approximately one week of
starting oral FK506. In our experiences, total oral daily
dose of FK506 which achieves 10–15ng/mL is approximately
0.1mg/kg per day. Therefore, we set our starting dose of
FK506 to 0.1mg/kg per day. Food intake is known to reduce
serum level of FK506 resulting from low absorption rate. We
recommend oral administration of FK506 one hour prior to
each meal.
In our hospital, intravenous CSA and oral FK506 were
used in total 58 moderate to severe refractory cases between
1999 and 2010. Two cases were treated with both CSA and
FK506. Excluding these two cases, CSA was used in 47 cases
andFK506wasusedin9cases.Diseaseactivitywasmeasured
by Seo’s CIDAI. Among 47 CSA cases, 56.5% were severe
cases. On the other hand, only 22.2% were severe cases in
FK506 cases. In line with this result, the decrease of Seo’s
CIDAI at one week after the administration of CNI CSA
was 55.9 point in CSA cases versus 22.4 point in FK506
cases (P<. 01). Switching of CNI was tried in two cases
due to induction failure (one case from FK506 to CSA, the
other case from CSA to FK506). However none of two case
was successful. Adverse event of oral FK506 was one case
with renal dysfunction. From our experiences, we choose
CSA treatment in the critical urgent cases because induction
therapy by using oral FK506 usually needs one to achieve
eﬃcacious serum levels.
Anti-TNFα-antibody (inﬂiximab) became an alternative
for refractory UC from July in 2010 under Japanese national
health insurance. As the induction therapy of steroid-
refractory ulcerative colitis, there are at least four options
in Japan: (1) cytapheresis therapy (including “intensive”
regimen), (2) intravenous CSA, (3) oral FK506, and (4)
inﬂiximab. However, there are no guidelines of the sequence
and timing of these options. We have used inﬂiximab for 5
cases of CNI refractory UC. All of them are showing favor-
able response and having maintenance therapy. RandomizedISRN Gastroenterology 3
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Figure 1: Metabolism and transportation of AZA/6-MP and its metabolites. XO: Xanthine oxidase, TPMT: thiopurine S-methyltransferase,
HGPRT:hypoxanthine–guaninephosphoribosyltransferase,ITPA:inosinetriphosphatepyrophosphatase,IMPDH:inosinemonophosphate
dehydrogenase, GMPS: guanosine monophosphate synthetase, AZA: azathioprine, 6-MP: 6-mercaptopurine, 6-TUA: 6-thiouric acid,
6-MeMP: 6-methylmercaptopurine, 6-MeMPR: 6-methylmercaptopurine ribonucleotide, 6-TIMP: 6-thioinosine monophosphate, 6-
TIDP: 6-thioinosine diphosphate, 6-TITP: 6-thioinosine triphosphate, 6-MeTIMP: 6-methylthioinosine monophosphate, 6-MeTITP:
6-methylthioinosine triphosphate, 6-TXMP: 6-thioxanthosine 50-monophosphate, 6-TGN: 6-thioguanine nucleotide, 6-MeTGN: 6-
methylthioguanine nucleotide (redrawn from [7]).
study comparing intravenous CSA and inﬂiximab is ongoing
in the United States. More of such studies are expected to
accumulate knowledge on the emerging drugs.
3. Azathioprine (AZA) and
6-Mercaptopurine(6-MP)
The thioguanine derivative, AZA, is a prodrug of 6-MP
that is further metabolized by various enzymes (Figure 1).
Although their exact mode of action is still unknown, the
mode of action of AZA is thought to be multifactorial:
(1) acting as a purine antimetabolite, (2) preventing pro-
liferation of cells involved in the immune response, (3)
damage to DNA through the incorporation of thiopurine
analogues, resulting in altering lymphocyte function, reduce
thenumberoflaminapropriaplasmacells,andaﬀectnatural
killer cell function [10].
The thiopurine drugs AZA and 6-MP are the most com-
mon drugs used to maintain clinical remission in Crohn’s
disease and UC [11–13] .T h e s ed r u g sa r ea l s oi m p o r t a n ta s
steroid-sparing agents in chronic active inﬂammatory bowel
diseases. However, concerns remain regarding drug-induced
toxicity, such as bone marrow suppression, hepatotoxicity,
pancreatitis, fever, rash, and gastrointestinal intolerance [14,
15]. These drugs have to be discontinued due to side
eﬀects in about 15–30% of patients [16–19]. In Western
countries, an AZA dosage of 2-3mg/kg is recommended
for the treatment of IBD patients [20], but lower doses of
AZA (0.6–1.2mg/kg/day) are used in Japan because of the
relativelyheightenedsensitivity[21].Inourhospital,starting
dose of AZA is 25mg/day/body. Weekly blood test including
WBCcount,liverfunctiontest,andamylaseisdoneuntiltwo
to three months after AZA introduction.
The cytotoxic and immunosuppressive properties of
AZA/6-MP are mediated by 6-thioguanine nucleotide (6-
TGN), a metabolite of AZA/6-MP. 6-TGN incorporates into
the DNA, thus leading to DNA breakage and an inhibition of
immune cell proliferation [22]. Some patients are more sus-
ceptible to bone marrow toxicity while on AZA/6-MP ther-
apy. This susceptibility is genetically dependent on interindi-
vidual variations in thiopurine S-methyltransferase (TPMT)
enzyme activity, based on the genetic polymorphism of low-
metabolizingalleles[22].SeveralvariantTPMT allelesoflow
metabolization have been described recently in many ethnic
groups [23]. TPMT A719G (TPMT∗3C) is associated with
intermediate to low TPMT enzyme activity. However, the
frequency of TPMT A719G is around 2% in the Japanese
population. For largely unknown reasons, a subset of other
patients who have not inherited the TPMT deﬁciency also
experience thiopurine-induced myelotoxicity.
Genetic polymorphism of inosine triphosphate pyro-
phosphatase (ITPase) was also suspected as another factor
responsible for thiopurine intolerance. ITPase catalyses the
breakdown of inosine triphosphate as part of a futile
cycle in the purine metabolic pathway. Genetic ITPase
deﬁciency results in the cellular accumulation of thioinosine
triophosphate (TITP) following exposure to thiopurines.
Many recent studies have failed to prove an association
between the development of thiopurine toxicity and ITPase
polymorphism, although a few studies have suggested a role
for ITPase variants in thiopurine-induced toxicity.4 ISRN Gastroenterology
We have recently elucidated the multidrug-resistance
protein 4 (MRP4) polymorphism as a new factor accounting
for thiopurine sensitivity in Japanese patients [7]. Of the
279 samples analyzed (44 healthy volunteers and 235 IBD
patients), 68 samples showed a heterozygote of MRP4
G2269A and 7 carried a homozygote. The allelic frequency
of MRP4 G2269A was 14.7%. In 130 IBD patients treated
with AZA/6-MP, the white blood cell count was signiﬁcantly
lower in the patients with the MRP4 variant alone (n = 26)
than in patients with a wild allelotype (n = 74) (P = .014)
or in the patients with the ITPase variant alone (n = 22)
(P = .0095). The 6-TGN levels were signiﬁcantly higher
in patients with the MRP4 variant alone than in patients
with the wild allelotype (P = .049). Of the 15 patients who
experience leucopenia (<3 × 109/L), 7 patients carried the
MRP4 variant. The odds ratio of carrying the MRP4 variant
alone and having leucopenia was 3.30 (95% conﬁdence
interval 1.03–19.57, P = .036).
4. Conclusion
We have described the characteristics and usage of immun-
omodulatorsandimmunosuppressantsfocusingonJapanese
patients. As for immunosuppressants, eﬀectiveness of intra-
venous CSA is similar to the Western countries in remission
induction therapy. On the other hand, oral FK506 which
needs at least one week to exert eﬀectiveness is also an
alternative therapy in remission induction. Immunomodu-
lators such as AZA and 6-MP need special attention when
determining a dose. The metabolism of AZA and 6-MP is
largely aﬀected by various enzymes. Japanese patients need
lessAZA/6-MPtoobtainenough6-TGNconcentrationcom-
pared to Westerners. As medical options increase, decisions
about the sequence and timing of therapy become more
diﬃcult. Consequently a therapeutic strategy is necessary,
takingthemeasureofnotonlythediseaseseverityandcourse
but also the selected therapeutic options. Further evidence
should be accumulated to obtain the rapid induction of clin-
icalremission,steroid-freemaintenanceofclinicalremission,
avoidance of complications, hospitalizations and surgeries,
and improvement of quality of life.
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